tiprankstipranks
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
US Market
Holding DMAC?
Track your performance easily

Diamedica Therapeutics (DMAC) Earnings Date & Reports

479 Followers

Earnings Data

Report Date
Mar 25, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
-$0.17
Last Year’s EPS
-$0.12
Same Quarter Last Year
Based on 3 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 13, 2024
|
% Change Since: 50.47%
|
Next Earnings Date:Mar 25, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant progress in clinical programs and protocol updates designed to accelerate trial enrollment and enhance study quality. Financial resources appear sufficient to support ongoing activities. However, there were delays in site activations and increased R&D expenses.
Company Guidance
During the DiaMedica Therapeutics Q3 2024 earnings call, significant guidance was provided regarding their ongoing clinical trials and financial status. The company has activated 13 of its top 15 U.S. sites for the AIS study, with expectations to fully activate all top 5 sites by year-end. Canada will add 5 to 7 sites to rival U.S. recruitment rates. A protocol update aims to accelerate enrollment and target high-quality patients, leveraging a new drug lot for refrigerated storage, facilitating after-hours enrollment. The ReMEDy2 trial will now include thrombolytic nonresponders and increase interim analysis size from 144 to 200 participants, potentially reducing the total sample size and overall timeline, with interim results expected in Q4 2025. Financially, DiaMedica reported a cash position of $50.2 million as of September 30, 2024, with an anticipated runway through Q3 2026. Research and Development expenses rose to $5 million for Q3 2024, attributed to the ReMEDy2 trial continuation and team expansion.
Progress in Stroke and Preeclampsia Programs
Solid progress reported on stroke and preeclampsia programs, with 2025 expected to be transformative. Key sites in the AIS study are being activated, with contracts signed and site initiation visits scheduled. The preeclampsia program has secured regulatory approval in South Africa, and the first participant was enrolled.
Protocol Updates to Accelerate Enrollment
ReMEDy2 protocol updates include inclusion of thrombolytic nonresponders and an increase in interim analysis sample size from 144 to 200 participants. These changes aim to accelerate enrollment rates by 50% to 100% and improve overall response rates.
Financial Position and Cash Runway
As of September 30, 2024, the company has $50.2 million in cash, cash equivalents, and investments, providing a financial runway to Q3 2026.
---

Diamedica Therapeutics (DMAC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DMAC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 25, 20252024 (Q4)
-0.17 / -
-0.12
Nov 13, 20242024 (Q3)
-0.15 / -0.15
-0.12-25.00% (-0.03)
Aug 07, 20242024 (Q2)
-0.16 / -0.13
-0.1618.75% (+0.03)
May 08, 20242024 (Q1)
-0.16 / -0.14
-0.230.00% (+0.06)
Mar 19, 20242023 (Q4)
-0.14 / -0.12
-0.1414.29% (+0.02)
Nov 13, 20232023 (Q3)
-0.13 / -0.12
-0.120.00% (0.00)
Aug 14, 20232023 (Q2)
-0.18 / -0.16
-0.13-23.08% (-0.03)
May 15, 20232023 (Q1)
-0.16 / -0.20
-0.13-53.85% (-0.07)
Mar 28, 20232022 (Q4)
-0.14 / -0.14
-0.11-27.27% (-0.03)
Nov 09, 20222022 (Q3)
-0.15 / -0.12
-0.1833.33% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

DMAC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2024$4.26$4.12-3.29%
Aug 07, 2024$3.25$3.35+3.08%
May 08, 2024$3.47$3.25-6.34%
Mar 19, 2024$2.82$2.77-1.77%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Diamedica Therapeutics Inc (DMAC) report earnings?
Diamedica Therapeutics Inc (DMAC) is schdueled to report earning on Mar 25, 2025, TBA Not Confirmed.
    What is Diamedica Therapeutics Inc (DMAC) earnings time?
    Diamedica Therapeutics Inc (DMAC) earnings time is at Mar 25, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is DMAC EPS forecast?
          DMAC EPS forecast for the fiscal quarter 2024 (Q4) is -$0.17.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis